Pasireotide for malignant insulinoma.

Abstract

UNLABELLED Malignant insulinoma usually has a poor prognosis, as no efficient medical treatment is available. The somatostatin analogs octreotide and lanreotide have limited ability to control the hypoglycemic events. Pasireotide is a multi-receptor targeted somatostatin-analog with improved affinity for SSTR5. There is to date no reported treatment experience with this drug in such tumors. CASE DESCRIPTION A 72-year-old patient with a G2 stage IV insulinoma, who underwent excision of the primary pancreatic tumor and multiple hepatic metastases, required further treatment for recurrent hypoglycemic events. The glycemic control achieved with pasireotide LAR was better compared with lanreotide and everolimus. However, none of these treatments showed tumor anti-proliferative effects. CONCLUSIONS Pasireotide monthly injections achieved improved glycemic control in a patient with malignant insulinoma and recurrent hypoglycemic events compared with other medical treatments.

DOI: 10.14310/horm.2002.1639

Cite this paper

@article{Tirosh2016PasireotideFM, title={Pasireotide for malignant insulinoma.}, author={Amit Tirosh and Salomon Marcello Stemmer and Evgeny Solomonov and Eldad Elnekave and Wolfgang Saeger and Yelena Ravkin and Kobi Nir and Yeela Talmor and Ilan Shimon}, journal={Hormones}, year={2016}, volume={15 2}, pages={271-6} }